UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

The New England journal of medicine, 2022-02, Vol.386 (6), p.509-520

2022

Volltextzugriff (PDF)

Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections

Antimicrobial agents and chemotherapy, 2015-02, Vol.59 (2), p.864-871

2015

Volltextzugriff (PDF)

Molnupiravir: Mechanism of action, clinical, and translational science

Clinical and translational science, 2024-02, Vol.17 (2), p.e13732-n/a

2024

Volltextzugriff (PDF)

Population pharmacokinetics of molnupiravir in adults with COVID‐19: Lack of clinically important exposure variation across individuals

CPT: pharmacometrics and systems pharmacology, 2023-12, Vol.12 (12), p.1859-1871

2023

Volltextzugriff (PDF)

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial

The Lancet infectious diseases, 2014-08, Vol.14 (8), p.696-705

2014

Volltextzugriff (PDF)

Clinical Response of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections by Severity Measure Using a Pooled Analysis from Two Phase 3 Double-Blind Trials

Antimicrobial agents and chemotherapy, 2017-05, Vol.61 (5)

2017

Volltextzugriff (PDF)

Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

The Journal of infectious diseases, 2019-05, Vol.219 (10), p.1536-1544

2019

Volltextzugriff (PDF)

A multicenter analysis of the clinical microbiology and antimicrobial usage in hospitalized patients in the US with or without COVID-19

BMC infectious diseases, 2021-02, Vol.21 (1), p.227-227, Article 227

2021

Volltextzugriff (PDF)

Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP

Antimicrobial agents and chemotherapy, 2022-05, Vol.66 (5), p.e0139921-e0139921

2022

Volltextzugriff (PDF)

Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial

Critical care (London, England), 2021-10, Vol.25 (1), p.354-354, Article 354

2021

Volltextzugriff (PDF)

Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia

Journal of clinical pharmacology, 2023-03, Vol.63 (3), p.352-357

2023

Volltextzugriff (PDF)

Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections

Antimicrobial agents and chemotherapy, 2021-11, Vol.65 (12), p.e0089521

2021

Volltextzugriff (PDF)

Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial

The Journal of infection, 2023-11, Vol.87 (5), p.392-402

2023

Volltextzugriff (PDF)

Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022-09, Vol.28 (9), p.1235-1241

2022

Volltextzugriff (PDF)

Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

Infectious diseases and therapy, 2024-05, Vol.13 (5), p.1159-1160

2024

Volltextzugriff (PDF)

Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

Infectious diseases and therapy, 2023-12, Vol.12 (12), p.2725-2743

2023

Volltextzugriff (PDF)

Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)

Microbiology spectrum, 2024-03, Vol.12 (3), p.e0356323-e0356323

2024

Volltextzugriff (PDF)

Efficacy and Safety of Tedizolid and Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Injection Drug Users: Analysis of Two Clinical Trials

Infectious diseases and therapy, 2018-12, Vol.7 (4), p.509-522

2018

Volltextzugriff (PDF)

Clinician-reported lesion measurements in skin infection trials: Definitions, reliability, and association with patient-reported pain

Contemporary clinical trials, 2016-09, Vol.50, p.265-272

2016

Volltextzugriff (PDF)

Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial

JAMA : the journal of the American Medical Association, 2013-02, Vol.309 (6), p.559

2013

Volltextzugriff (PDF)

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

The New England journal of medicine, 2022-02, Vol.386 (6), p.509-520

2022

Volltextzugriff (PDF)

Molnupiravir for Covid-19 in Nonhospitalized Patients. Reply

The New England journal of medicine, 2022-03, Vol.386 (13), p.e32-e32

2022

Volltextzugriff (PDF)

A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

Clinical infectious diseases, 2021-08, Vol.73 (3), p.e710-e718

2021

Volltextzugriff (PDF)

Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: Subgroup analysis of 2 randomized phase 3 trials

Medicine (Baltimore), 2017-12, Vol.96 (52), p.e9163-e9163

2017

Volltextzugriff (PDF)

Factors Influencing COVID‐19 Risk: Insights From Molnupiravir Exposure‐Response Modeling of Clinical Outcomes

Clinical pharmacology and therapeutics, 2023-06, Vol.113 (6), p.1337-1345

2023

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(58)

Sprache

Englisch
(58)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(37)
Science & Technology
(37)
Humans
(28)
Infectious Diseases
(19)
Adult
(16)
Anti-Bacterial Agents - Therapeutic Use
(13)
Microbiology
(13)
Pharmacology & Pharmacy
(13)
Covid-19
(11)
Skin Diseases, Bacterial - Drug Therapy
(11)
Female
(10)
Male
(10)
Treatment Outcome
(10)
Sars-Cov-2
(9)
Clinical Trials
(8)
Double-Blind Method
(8)
Middle Aged
(8)
Patients
(8)
Adolescent
(7)
Aged
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections

Molnupiravir: Mechanism of action, clinical, and translational science

Population pharmacokinetics of molnupiravir in adults with COVID‐19: Lack of clinically important exposure variation across individuals

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial

Clinical Response of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections by Severity Measure Using a Pooled Analysis from Two Phase 3 Double-Blind Trials

Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

A multicenter analysis of the clinical microbiology and antimicrobial usage in hospitalized patients in the US with or without COVID-19

Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP

Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial

Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia

Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections

Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial

Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid

Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)

Efficacy and Safety of Tedizolid and Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Injection Drug Users: Analysis of Two Clinical Trials

Clinician-reported lesion measurements in skin infection trials: Definitions, reliability, and association with patient-reported pain

Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

Molnupiravir for Covid-19 in Nonhospitalized Patients. Reply

A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: Subgroup analysis of 2 randomized phase 3 trials

Factors Influencing COVID‐19 Risk: Insights From Molnupiravir Exposure‐Response Modeling of Clinical Outcomes

Suchergebnisse filtern